Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mapatumumab with Carboplatin and Paclitaxel in Advanced NSCLC
NCT00583830Phase 2Completed
- Sponsor
- Human Genome Sciences
- Start
- Jan 2007
- Primary completion
- Nov 2010
- Modality
- Monoclonal Antibodies
- Countries
- 4
01
Overview
Phase 2, randomised, open-label trial of mapatumumab in non-small cell lung cancer (NSCLC) (3 arms), sponsored by Human Genome Sciences. Primary endpoints: Objective Response Rate and Progression-Free Survival. Started Jan 2007; status: completed.
02
Drugs
mapatumumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00583830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00583830.